[WS(P)03] In vivo model and new cancer immunotherapy

[WS03-02-P] A novel biparatopic TIM-3 antibody induces superior antitumor effects through multi-ligand blockade

^○Kanto Nakajima¹, Yuji Mishima¹, Motoya Mie¹, Norihiro Nakamura¹, Junichiro Yuda² (1.BrightPath Biotherapeutics Co., Ltd., 2.Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East)

キーワード：

Cancer、Antibody、Engineered antibodies、Immunotherapy、Checkpoint blockade、cytotoxic T lymphocytes、Effector cells、Tumor microenvironment、Self-renewal

閲覧にはパスワードが必要です

ログイン

または